Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

177.44 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
80 81 Next >
AbbVie Unusual Options Activity
Via Benzinga
2 No-Brainer Dividend Stocks to Buy This Week
These two top-income stocks are too cheap to ignore. 
Via The Motley Fool
AbbVie To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
AbbVie Inc. Dividend Increase
AbbVie Inc. recently announced its next dividend of $1.55 per share, a 4.73% increase over the company's previous payout of $1.48. 
Via Talk Markets
Why AbbVie Stock Fell Today
AbbVie stock fell despite beating third-quarter expectations and raising its full-year outlook. Here's what investors need to know. 
Via The Motley Fool
AbbVie (ABBV) Q3 2023 Earnings Call Transcript
ABBV earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Earnings Outlook For AbbVie
Via Benzinga
AbbVie Unusual Options Activity
Via Benzinga
Is AbbVie Stock Too Pricey to Touch Right Now?
Other pharmaceutical companies are trading for far lower multiples. 
Via The Motley Fool
FDA Gives Nod To Eli Lilly's First Treatment For Type Of Inflammatory Bowel Disease, To Compete With JNJ, Pfizer, AbbVie
The FDA approved Eli Lilly And Co's  
Via Benzinga
Exposures Product Safety
AbbVie Raises Annual Profit Outlook As Newer Immunology Drugs Help Cushion Struggling Humira Sales
AbbVie Inc (NYSE: ABBV) has reported Q3 adjusted EPS of $2.95, down 19.4% Y/Y, beating the consensus of $2.88. 
Via Benzinga
High-yield, deep-value AbbVie fell off the patent cliff and lived
AbbVie's deep value and high yield attract income investors, and the patent cliff worry lessens daily. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
AbbVie Stock Slips As Humira Struggles Continue, But Drugmaker Raises Outlook
Humira sales continued to decline amid a battle with new biosimilars in the U.S. 
Via Investor's Business Daily
Got $1,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond
The market has punished them, but don't overlook these stocks. 
Via The Motley Fool
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Earnings Scheduled For October 27, 2023
Companies Reporting Before The Bell • Sanofi (NASDAQ:SNY) is projected to report quarterly earnings at $2.26 per share on revenue of $12.56 billion. 
Via Benzinga
The 7 Best Forever Stocks to Buy for October 2023
These forever stocks have held up incredibly well despite the economic troubles offering healthy upside compared to its peers. 
Via InvestorPlace
Pivotal Week Coming Up: Big Tech Earnings, Geopolitics, Technicals, Treasury Yield...
The upcoming quarter GDP is expected to hit 3.7% which has brought the FED dialogue to “higher rates for longer” which might lead us to a recession in 2024. So watch the yield on the 10-year TSY now at... 
Via Talk Markets
Topics Economy
Exposures Economy
Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:LIPO) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
Investor Risk Sentiment Wavers Amid War, Interest Rate Concerns; Tesla Earnings Disappoint: The Week In The Markets
In the week ahead, earnings season moves into full swing with reports from companies like Microsoft, Alphabet, Meta Platforms and Amazon. 
Via Benzinga
7 Dividend Stocks to Buy and Hold Forever and Ever
Investors must consider long-term dividend stocks to buy for their safety as markets remain turbulent in mid-October. 
Via InvestorPlace
7 Dividend Aristocrats to Batten Down the Hatches
With uncertainty clouding the capital market ecosystem, investors may take confidence with these dividend aristocrats. 
Via InvestorPlace
Is Johnson & Johnson Still a Good Dividend Stock to Buy?
Investors wonder if the healthcare giant can keep raising its payout now that it no longer sells the consumer health brands that made it famous. 
Via The Motley Fool
Takeda's Crohn's Disease Fistulas Candidates Fall Short In Mid-Stage Study, Settles Tax Dispute With Irish Revenue Commissioners
Takeda Pharmaceutical Co Ltd (NYSE: TAK) released topline data from the Phase 3 ADMIRE-CD II study, assessing Alofisel (darvadstrocel) for complex Crohn's Perianal Fistulas (CPF). 
Via Benzinga
Is the "New" Johnson & Johnson Stock a Buy With Its Improved Profit Outlook?
Some things are different about J&J. But other things remain the same as they've been for a long time. 
Via The Motley Fool
Johnson & Johnson Was Saved By Its Focus On MedTech And Innovative Medicine
Johnson & Johnson (NYSE: JNJ) reported its third quarter results that topped Wall Street’s expectations while also lifting its full year guidance fueled by a strong performance of its pharmaceutical... 
Via Benzinga
3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off
These three top-notch stocks would make great additions to any dividend portfolio. 
Via The Motley Fool
Healthcare Portfolio Focus Stocks
The macro news has been a steady headwind with rising rates offering 5% risk-free treasury yields. 
Via Talk Markets
Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout
MoonLake says it's skin-disease treatment showed improved promise in a 24-week testing update. 
Via Investor's Business Daily
3 Dividend Growth Stocks You Can Buy and Hold Forever
Investors can sit back and let the dividends flow in with these great stocks. 
Via The Motley Fool
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
80 81 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.